NLRP3 and congenital rubella syndrome: Similarly, the IL-1 receptor antagonist anakinra improves CAR-T cell therapy CRS outcomes and also significantly increases survival of SARS-CoV-infected mice with hyperactive NLRP3 inflammasomes (186, 189, 190).